Kornimate/medical-research-clean huggingface dataset:
sebum excretion in neonates of women with polycystic ovary syndrome (pcos)

Conditions: Polycystic Ovary Syndrome

Summary: to investigate whether women with polycystic ovary syndrome who are post-partum excrete higher levels of sebum in comparison to healthy controls due to high levels of androgens.

first degree relatives of women with pcos have a 3-4 fold increased prevalence of the syndrome compared with the general population, suggesting an inherited genetic predisposition. many investigations into possible candidate genes for pcos susceptibility have hypothesised the incomplete penetrance of a dominant gene, although no consensus has been achieved as to any exact genetic polymorphisms which may be culpable. primate studies have offered credence to the theory that genomic imprinting is influenced by environmental hyperandrogenism and the hypothesis of intra-uterine exposure to excess androgens as a cause of pcos is gaining momentum (abbott et al, 2010). at birth, both mother and neonate are influenced by an identical hormone profile, and it is therefore expected that sebum excretion rates (a correlate of androgen excess) will be higher in those neonates born to mothers with pcos when compared to those without. this would account for the observed familial transition of pcos (legro et al, 1998; vink et al, 2006), and support the hypothesis that in-utero hyperandrogenism primes differentiating tissues for later expression of the pcos phenotype in adolescence.

Eligibility criteria:
inclusion criteria: * women (with and without a diagnosis of polycystic ovarian syndrome) aged 18-40 with an uncomplicated singleton pregnancy, who deliver a female baby at term (37 weeks gestation or longer). women in the pcos cohort will be defined by all the eshre/asrm rotterdam criteria. women in the control group, non-pcos who deliver a female baby will be age matched to the pcos group. conception method (natural/assisted) and maternal parity does not affect inclusion but will be documented for subsequent analysis. exclusion criteria: * baby boys
disease progression and treatment-induced alterations in glioblastoma

Conditions: Brain Tumor

Summary: summary of scientific evidence and rationale of this project: integrative molecular-genetic approaches have provided important insights in the biology of glioblastoma. it has meanwhile become clear, that glioblastoma is not a single tumor entity but comprises different molecular subtypes, which are associated with a distinct genetic/epigenetic signature and prognosis. multimodal treatment approaches combining radio- and chemotherapy as well as the recent introduction of novel antiangiogenic agents have resulted in increasing survival times and improved quality-of-life of glioblastoma patients. yet, despite these intense treatment efforts the therapeutic efficacy in glioblastoma patients is limited, leading in virtually all cases to tumor recurrence and death of the patients. as only a limited fraction of glioblastoma patients undergo second neurosurgery at tumor recurrence (\< 10%), post-therapeutic samples are rare and no systematic, large-scale studies exist, which address post-therapeutic morphological and molecular alterations in glioblastoma tumor tissue. yet, these data would help to improve the understanding of mechanisms involved in therapy-resistance and tumor progression, to develop new therapeutic approaches and could pave the way for personalized treatment strategies.

objectives of the project: the aim of this study is to analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance in matched pre- and post-therapeutic glioblastoma samples. the following primary aims will be addressed: 1. morphological characterisation of changes in a large series of matched glioblastoma tissues pertaining to i. vascularization and hypoxia-mediated factors ii. tumor necrosis and chemoradiation-induced necrosis iii. inflammatory response iv. tumor cellularity and proliferation v. tumor cell phenotype after treatment e.g. glial-mesenchymal transition 2. molecular analyses i. transcriptomic, dna methylation and genomic profiling will be performed to detect changes in gene expression, methylation and copy number aberrations in post-therapeutic as compared to pre-therapeutic tumor tissue. ii. the relationship between the transcriptomic, dna methylation and genomic profiles will be analyzed. 3. exploratory analysis of associations between morphological and molecular changes in a screening set of 30 glioblastoma cases (with available fresh frozen tissues at first and second surgery) and subsequent validation of relevant findings in a larger glioblastoma cohort (150 cases with matched formalin-fixed paraffin-embedded tissues) by appropriate methods including immunohistochemistry, fluorescence-in-situ-hybridization, and sequencing. 4. special attention will be paid to gender-specific patterns of therapy-related changes and tumor progression.

Eligibility criteria:

Keywords: glioblastoma morphological and molecular changes progression therapy-resistance
evaluation of the efficacy and safety of advantage® strips in women stress urinary incontinence (sui )

Conditions: Urinary Incontinence

Summary: this is a single-center retrospective study that evaluates the effectiveness and long-term safety of the tvt tape ( advantage boston scientific) in the treatment of stress urinary incontinence in women on a population of 500 patients with a mean follow-up of 6 years.


Eligibility criteria:
inclusion criteria: * patient who received the laying of a strip advantage between 1/1/2015 and 1/6/2012 exclusion criteria: * no
a clinical trial to assess the safety of sor102 in healthy participants and patients with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: sor102-101 is a phase 1, 3-part, randomised, double-blind, placebo-controlled, fih study to determine the safety, tolerability, and pk of single, ascending oral doses (sad) of sor102 (part 1) and multiple oral doses (part 2) of sor102 in healthy adult participants, and to assess the safety, tolerability, pk, and biological activity of multiple oral doses of sor102 in patients with mild to severe uc (part 3).


Eligibility criteria:
key inclusion criteria: * male or females, of any ethnic origin. * established diagnosis of uc by standard criteria for \>3 months. * disease evaluable by sigmoidoscopy. * mildly to severely active uc as determined by central reader in combination with other assessments of disease key exclusion criteria: * any diagnosis of ibd except for uc. * history of fistula(e), strictures or surgery, known intestinal obstruction, or diagnosis of toxic megacolon. * concurrent use of any biologic drug. * prior primary efficacy failure or secondary loss of response to more than one biologic or new small molecule therapy (i.e., jak inhibitors or s1p receptor modulators) indicated for the treatment of uc. this does not include prior discontinuation due to drug intolerance.
comparison of insulin detemir and nph with respect to lowering the blood sugar and symptoms experienced by type 1 diabetics during hypoglycaemia

Conditions: Diabetes; Diabetes Mellitus, Type 1

Summary: this trial is conducted in uk. the aim of this clinical trial is to investigate lowering the blood sugar and symptoms experienced during hypoglycaemia


Eligibility criteria:
inclusion criteria: * signed and dated informed consent obtained before any trial-related activities. * type 1 diabetes * treatment with insulin for minimum three months * duration of diabetes for more than 12 months * body mass index (bmi) less than 30 kg/m2 * hba1c equal to or greater than 10 % based on analysis from central laboratory exclusion criteria: * participation in any other clinical trial involving other investigational products within the last three months * current treatment with insulin in a daily dose above 100 u * episode of symptomatic hypoglycaemia, or a capillary plasma glucose value of less than 3.5 mmol/l in the past two weeks * hypoglycaemic unawareness or severe autonomic neuropathy * current treatment with drugs known to interfere with glucose metabolism such as systemic corticosteroids, non-selective beta-blockers and mao inhibitors * current treatment with oral antidiabetic drugs * impaired hepatic function measured as alat of more than two times the upper reference limit * impaired renal function measured as creatinine of more than 150 micromol/l (1.7 mg/dl) * cardiac problems defined as decompensated heart failure (nyha class iii and iv) at any time and/or angina pectoris and/or myocardial infarction within the last 12 months * known or suspected allergy to trial product or related products * mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation * blood donation of more than 500 ml within the last three months * any condition that the investigator and/or the sponsor feels would interfere with study participation or evaluation of results * pregnancy or intention of becoming pregnant, breast-feeding or judged to be using inadequate contraceptive methods. adequate contraceptive methods are sterilisation, intrauterine device (iud), oral contraceptives or consistent use of barrier methods * previous participation in this trial
factors predicting positive yields on biliary brush cytology during endoscopic retrograde cholangiopancreatography

Conditions: Biliary Stricture

Summary: to determine factors associated with a positive yield of malignancy on biliary brush cytology obtained by ercp.

there are only 3 studies available that have tried to evaluate factors influencing the yield of brush cytology. two of the 3 studied one parameter. the third study, which is also the largest, reported on 199 samples which the authors evaluated in a retrospect fashion. we plan to conduct a larger study assessing several other factors that have not been studied before. the study findings would help develop strategies to improve sensitivity of brush cytology specimens. this would ultimately result in more effective use of health care resources and improve patient outcomes.

Eligibility criteria:
inclusion criteria: * ercp patients exclusion criteria: * non ercp patients

Keywords: ercp positive biliary brush cytology
the effects of intraoperative dexmedetomidine infusion on postoperative bowel movement in patients undergoing laparoscopic gastrectomy

Conditions: Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy

Summary: the investigators hypothesized that sympatholytic effect of dexmedetomidine would attenuate the hemodynamic instability and decrease in the splanchnic blood flow caused by pneumoperitoneum during laparoscopic surgery. this study is to investigate the effect of intraoperative dexmedetomidine infusion on postoperative bowel movement in patients undergoing laparoscopic gastrectomy.


Eligibility criteria:
inclusion criteria: * patient between 20 and 65 of age with asa physical status ⅰ-ⅲ * gastric cancer patient undergoing laparoscopic gastrectomy exclusion criteria: * asa physical status ⅳ * bradycardia (\< 60 bpm), arrhythmia * uncompensated heart failure * hepatic failure (child-pugh score b 이상) * renal failure (egfr mdrd \< 60 ml/min/1.73m2)

Keywords: dexmedetomidine postoperative bowel movement laparoscopic gastrectomy
retinal oxygen reactivity in patients infected with human immunodeficiency virus (hiv)

Conditions: HIV Infections; Retina; Ocular Physiology

Summary: ocular lesions, including cotton wool spots and retinal hemorrhage, are a common feature of hiv infection and acquired immunodeficiency syndrome (aids). the aetiology of these apparently vasoocclusive phenomena in hiv related retinopathy is not well understood. several hypotheses including infectious damage of the retinal vasculature and altered retinal hemodynamics have been postulated. the latter would be compatible with the theory that the retina of hiv patients is hypoxic. however, direct measurement of oxygen tension in the retina is not possible and indirect methods have to be employed. the study objective was to investigate the reactivity in retinal blood flow to 100% oxygen breathing in patients with hiv.


Eligibility criteria:
inclusion criteria: group 1 (patients with hiv) * aged between 19 and 70 years, male and female * hiv positive patients without hiv-related retinopathy with a cd4+ cell count  500 cells/mm3 stage a2, a3, b2, b3, c2 and c3. * best corrected visual acuity \>= 0.8 * ametropy \< 6 dpt group 2 (healthy control subjects) * aged between 19 and 70 years * age and sex matched to the subjects in the hiv group (group matched) * matched with regard to the smoking habits in the hiv group * best corrected visual acuity \>= 0.8 * ametropy \< 6 dpt exclusion criteria: * evidence of any other eye disease * diabetes mellitus * systemic hypertension (defined as sbp \> 150 mmhg or dbp \> 90 mmhg) * abuse of illegal drugs
inhaled nitric oxide in neonates with elevated a-a do2 gradients not requiring mechanical ventilation

Conditions: Lung Disease; Hypoxemia; Respiratory Acidosis

Summary: the purpose of this pilot study is to evaluate whether administration of nitric oxide (no)gas by oxygen hood at 20 ppm significantly increases pao2, as compared to placebo gas (oxygen), within one hour of initiation and with no significant adverse effects.

it is possible that administration of inhaled no to neonates with abnormal gas exchange earlier, rather than later as a rescue therapy in a moribund state, might accelerate the transition of the circulation from the fetal to neonatal physiology and improve oxygenation. this may in turn decrease the need for mechanical ventilation, its associated morbidity and perhaps even ecmo. this study is designed as a pilot study to evaluate the physiologic efficacy (rather than effect on clinical outcomes) of no administered by hood in improving oxygenation of neonates with elevated a-a do2.

Eligibility criteria:
inclusion criteria: * gestational age \>34 completed weeks (\>=35) * age \<48 hours * a-a do2 400 to 600, on two post-ductal arterial blood gases one hour apart, while on 100% o2 by oxygen hood * post-ductal arterial access * admitted to the university of alabama birmingham regional nicu exclusion criteria: * cardiac disease (structural disease with right to left or mixing lesions), not including patent ductus arteriosus (pda) or patent foramen ovale (pfo) * rapid deterioration requiring mechanical ventilation before entry into the study * major malformations * major neurologic or metabolic disorder or other illness leading to hypoventilation and hypercarbia
tailored therapy for helicobacter pylori treatment in patients with penicillin allergy

Conditions: Helicobacter Pylori Infection

Summary: increasing drug resistance presents a significant challenge to the efficacies of common empiric eradication regimens for helicobacter pylori treatment in the mainland of china. tailored therapy may be the best choice to achieve good efficacy, especially in patients with penicillin allergy. few studies had evaluated the patients with penicillin allergy.this study is designed to evaluate the efficacy and safety of antibiotic sensitivity-based tailored therapy for helicobacter pylori treatment in the patients with penicillin allergy.


Eligibility criteria:
inclusion criteria: * participants with penicillin allergy who have non-ulcer functional dyspepsia or scarred peptic ulcer disease * ability and willingness to participate in the study and to sign and give informed consent * confirmed h. pylori infection exclusion criteria: * patients without penicillin allergy * less than 18 years old * with previous gastric surgery * major systemic diseases * pregnancy or lactation * allergy to any of the study drugs * administration of antibiotics, bismuth, antisecretory drugs in 8 weeks prior to inclusion

Keywords: helicobacter pylori tailored therapy penicillin allergy antimicrobial susceptibility testing
evaluation of influenza h1n1 vaccine in adults with lymphoid malignancies on chemotherapy

Conditions: Lymphoma; Multiple Myeloma; Influenza A Virus, H1N1 Subtype

Summary: the purpose of this study is to determine whether adults with hematologic malignancies on active systemic therapy or shortly after bone marrow transplantation need one or two doses of adjuvanted vaccine to achieve best possible rates of protection. an additional research question is whether baseline biomarkers of the cellular and humoral immune systems are associated with an antibody response to vaccination.

the novel influenza h1n1 virus responsible for a world-wide pandemic throughout 2009 (h1n1(2009)) is expected to cause a second wave of infection during the 2009/10 winter season. vaccines against h1n1(2009) will be available in early november, 2009. adults with hematologic disorders are at high risk of influenza-related complications, including death. given that the vaccination dosing for the pandemic vaccine has been developed on healthy individuals, it is unknown whether this subgroup of patients will respond similarly. we will evaluate the safety and efficacy of the pandemic vaccine in patients with lymphoid malignancies receiving active systemic treatment, or who have recently undergone stem cell transplantation. patients will be randomized to one or two doses of the approved adjuvanted vaccine; immune responses will be measured to identify the optimal regimen. also, we will look for an association between biomarkers of the immune system and a response to the vaccine; this will be done by measuring baseline cd3, 4, 8, 19, and 56 cells by flow cytometry.

Eligibility criteria:
inclusion criteria: * male or female, ages 20-65 * diagnosis of lymphoproliferative disorder * one of the following types of systemic treatment: active chemo/immunotherapy at enrollment or completed within the last 3 months, or auto/allo stem cell transplant recipient within the past 12 months * able to provide consent and comply with trial requirements exclusion criteria: * systemic hypersensitivity to hen's eggs, thimerosal, gentamicin * history of life-threatening reaction to prior influenza vaccination * thrombocytopenia or bleeding disorder contraindicating im injection * pregnancy * laboratory-confirmed infection with h1n1(2009) * ivig infusion within the last three months

Keywords: lymphoma multiple myeloma leukemia, lymphocytic, chronic, b-cell influenza a virus, h1n1 subtype influenza vaccines bone marrow transplantation
resection location of rectum in laparoscopic surgery for slow transit constipation

Conditions: Slow Transit; Constipation

Summary: study the recurrence rate of constipation after laparoscopic total colectomy with high resection or low resection of rectum

the investigators are going to study the recurrence rate of constipation after laparoscopic total colectomy with high resection or low resection of rectum. high resection is defined as resection at 12\~15cm from anus and low resection as 6\~8cm.

Eligibility criteria:
inclusion criteria: * diagnosed as constipation according to rome iv criteria * diagnosed as slow transit constipation * with more than 2 years' drug treatment or with outlet obstruction or with surgical history exclusion criteria: * colon cancer * history of colon, rectum, anus surgery * with severe cardio, renal, neural disease * pregnant patients
a follow-up evaluation for safety in subjects who participated in a phase 1 study with bms-986094 (inx-08189)

Conditions: Healthy; Hepatitis C

Summary: the purpose of this study is to determine the rate of kidney or heart impairment, if any, in subjects who received bms-986094 (inx-08189) in phase 1 clinical trials


Eligibility criteria:
inclusion criteria: * healthy and hepatitis c virus (hcv)-infected subjects who participated in prior phase 1 trial with bms-986094/inx-08189 and: 1. received at least 1 dose of inx-08189 or 2. received placebo in studies for hcv-infected subjects (inh-189-002 or inh-189-006) * age 18 or older exclusion criteria: -

Keywords: volunteers
non-surgical treatment of chronic periodontitis with an adjunctive vitamin e and coenzyme q10 supplementation

Conditions: Periodontal Diseases

Summary: non-surgical treatment of chronic periodontitis with vitamin e and coenzyme q10 supplementation

this research was structured as a double-blind, randomized clinical trial to assess the effectiveness of coq10 and vitamin e supplements on periodontal health in patients with chronic periodontitis. a total of 120 patients from the department of periodontics at boroujerd dental school of the islamic azad university of medical sciences were chosen for the study. before the commencement of the trial, various clinical periodontal parameters such as plaque index, bleeding on probing, gingival index, probing depth, and clinical attachment level were measured in six different areas of the tooth surface. subsequently, scaling and root planning were carried out, and oral hygiene practices were enhanced for all participants. the participants were then randomly divided into three groups: group a received 30 mg of coq10, group b received 400 mg of vitamin e supplements daily, and group c did not receive any medication. after two months, the clinical periodontal parameters were reevaluated. furthermore, to compare the total antioxidant capacity in saliva before and after the administration of these supplements, as well as in patients who did not receive any medication, 2 ml of non-stimulated saliva was collected from each participant at the beginning and end of the study for analysis using uv-spectrophotometric methods. the selection criteria for eligible participants in this study were also clearly defined.

Eligibility criteria:
inclusion criteria: healthy individuals, between the ages of 28 and 35, there is a presence of chronic initial periodontal disease, now categorized as stage-i, with a maximum pocket depth of 5 mm, specifically affecting the mandibular molar teeth in every quadrant. exclusion criteria: conditions that may affect orthodontic treatments include systemic diseases, ongoing orthodontic treatments, pregnancy and breastfeeding, and the use of medications that can impact the periodontium, such as antibiotics, within the past 6 months. additionally, recent malignancy, radiotherapy, or chemotherapy within the past 5 years can also have an impact. it is important to consider factors such as plaque index and bleeding scores, which should be below 25%, as well as any history of periodontal surgery at the desired treatment site within the past 6 months. furthermore, the use of medicinal supplements within the past 6 months and cigarette smoking or tobacco use should also be taken into account. eligibility criteria: the study population consisted of 80 eligible individuals who were enrolled in this research project, which was specifically designed to conduct randomized double-blind clinical trials.

Keywords: periodontal disease, coq10, vitamin e, antioxidant, saliva.